Description

BSE notification regarding the listing of 15,099,200 equity shares of Modern Diagnostic & Research Centre Limited with various lock-in periods.

Summary

BSE has listed 15,099,200 fully paid equity shares of Modern Diagnostic & Research Centre Limited. All securities are in dematerialized form with varying lock-in periods across 11 tranches. The lock-in expiry dates range from February 2026 to January 2029.

Key Points

  • Total equity shares listed: 15,099,200
  • All securities are fully paid and in demat form
  • Securities divided into 11 distinct tranches with different lock-in periods
  • Distinctive number range: 1 to 15,099,200
  • Earliest lock-in expiry: February 3, 2026 (577,600 shares)
  • Latest lock-in expiry: January 20, 2029 (3,120,000 shares)

Regulatory Changes

Not applicable. This is a listing notification rather than a regulatory change.

Compliance Requirements

  • All listed securities must remain in dematerialized form
  • Lock-in restrictions must be observed until respective expiry dates
  • Trading in locked-in securities is prohibited until lock-in period expires

Important Dates

  • February 3, 2026: Lock-in expiry for 577,600 shares
  • April 4, 2026: Lock-in expiry for 584,000 shares
  • January 20, 2027: Lock-in expiry for 3,620,000 shares (3 tranches)
  • January 20, 2028: Lock-in expiry for 5,520,000 shares (4 tranches)
  • January 20, 2029: Lock-in expiry for 3,120,000 shares

Impact Assessment

Market Impact: Medium. The listing adds 15.1 million shares to the market, though liquidity will be limited initially due to lock-in periods. Gradual unlock starting February 2026 will progressively increase tradable float over a 3-year period.

Operational Impact: The staggered lock-in structure suggests a controlled release mechanism, potentially from promoters, pre-IPO investors, or a combination thereof. The majority of shares (12.24 million) are locked until 2027-2029, limiting immediate trading activity.

Impact Justification

New equity listing of 15.1 million shares with staggered lock-in periods ranging from February 2026 to January 2029, indicating a significant corporate action for the company.